바카라 규칙 Pharmaceutical signs export deal with Mexican pharmaceutical company for GLP-1 obesity and diabetes drugs

[by Ji, Yong Jun] Hanmi Pharmaceutical (hereinafter referred to as Hanmi) announced on January 28 that it has entered into an exclusive distribution agreement with the Mexican pharmaceutical company Laboratorios Sanfer (hereinafter referred to as Sanfer) covering the glucagon-like peptide 1 (GLP-1)-based obesity treatment ‘efpeglenatide,’ as well as the ‘Daparon family’ of diabetes treatment combination therapies.

Under the terms of the agreement, 바카라 규칙 will supply efpeglenatide as well as finished products from its flagship diabetes treatment portfolio, the Daparon family (Daparon tablets and Daparon Duo Extended-Release tablets). Sanfer will assume responsibility for regulatory licensing, marketing, distribution, and sales of these products in the Mexican market.

According to a disclosure released by Hanmi on the same day, the export supply agreement covering ‘Daparon Tablets and Daparon Duo Extended-Release Tablets’ has a total contract value of KRW 65.8 billion (approximately USD 46.1 million). The agreement has a term of ten years, ending on January 26, 2036, with the stated value comprising milestone payments and projected sales over the next ten years agreed upon by both parties. Hanmi noted that actual sales over the contract duration may vary depending on external factors, including inflation, exchange rate volatility, the emergence of competitors, and potential drug price reductions.

Mexico is recognized as a representative ‘high-obesity’ country, with an obesity prevalence of 36.86% and a diabetes prevalence of 16.4%, alongside high demand for glycemic control even during the post-weight loss maintenance phase. Hanmi explained that this agreement reflects the global scalability and strategic value of efpeglenatide, given Mexico's market characteristics.

Founded in 1941, Sanfer is the largest privately held 바카라 규칙 company in Mexico. The company maintains a leading position in the regional market through a robust sales and distribution network across Latin America, supported by in-house R&D capabilities. Sanfer currently operates in approximately 20 Latin American countries, including Mexico, as well as in the United States. Following its recent acquisition of bio바카라 규칙 company Probiomed, Sanfer has further strengthened its position, emerging as the largest bio바카라 규칙 company in Mexico.

Through this partnership, the two companies plan to gradually broaden their collaboration, encompassing efpeglenatide and other therapies for metabolic disease. Over the mid- to long-term horizon, they also intend to explore the introduction of additional products and the development of joint marketing strategies.

"In Mexico, approximately 34.6% of household expenditures are spent on healthcare, making the reduction of the healthcare burden and the assurance of access to innovative treatments critical challenges. Hanmi's lineup of novel obesity and diabetes treatments is well aligned with these needs, and through this partnership, we aim to contribute meaningfully to addressing the rapidly rising prevalence of obesity and diabetes in Mexico," said Ricardo Amtmann, CEO of Laboratorios Sanfer.

"This agreement represents a meaningful milestone that demonstrates our company's advanced formulation technology and R&D competitiveness on the global stage,” said Park Jae-hyun, CEO of Hanmi Pharmaceutical. “As the Mexican government places greater emphasis on standardizing healthcare services and strengthening chronic disease management, we are honored that our company's first GLP-1-based obesity and metabolic disease treatment, together with our innovative diabetes treatment portfolio, can contribute to improving the health and well-being of the Mexican population," he added.